Compare MLP & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLP | TVRD |
|---|---|---|
| Founded | 1909 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.2M | 246.5M |
| IPO Year | 1972 | N/A |
| Metric | MLP | TVRD |
|---|---|---|
| Price | $17.35 | $4.20 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $51.67 |
| AVG Volume (30 Days) | 45.7K | ★ 114.5K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $18,344,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 73.55 | N/A |
| 52 Week Low | $13.84 | $3.74 |
| 52 Week High | $23.41 | $43.65 |
| Indicator | MLP | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 63.72 | 32.08 |
| Support Level | $16.05 | $4.05 |
| Resistance Level | $17.56 | $4.71 |
| Average True Range (ATR) | 0.59 | 0.27 |
| MACD | 0.20 | 0.50 |
| Stochastic Oscillator | 84.62 | 48.45 |
Maui Land & Pineapple Co Inc is a landholding and operating company. ML&P owns, develops, sells, and manages residential, resort, commercial, agricultural, and industrial real estate. It operates in three segments: Land Development & Sales which includes land planning and entitlement, development, and sales activities; Leasing operations include residential, resort, commercial, agricultural, industrial land and property leases; and Resort Amenities segment, which include a membership program that provides certain benefits and privileges within the Kapalua Resort for its members. The majority of its revenue is derived from the Leasing segment. Leasing revenue is generated from restaurants, retail outlets, office buildings, warehouses, and other resort activities.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.